Hospital
North Shore Medical Center, INC.
North Shore Medical Center, INC. was paid $4.42M by Medicaid between Jan 2018 and Oct 2021, across 187 billing codes. Its largest line is A4216, Sterile water, saline and/or dextrose, diluent/flush, 10 ml — 16% of everything it billed.
33Billing provider infoNORTH SHORE MEDICAL CENTER, INC.
MIAMI, FL 33150
MIAMI, FL 33150
33aNPI1720019995assigned 07/06/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.42M
24GClaims326,355
24DCodes billed187
24AFirst – last monthJan 2018 – Oct 2021
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#87 of 163
Median peer was paid$4.77M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 42,111 | $622K | |
| 2019 | 144,221 | $1.86M | |
| 2020 | 89,534 | $1.20M | |
| 2021 | 50,489 | $733K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 16% | 6,642 | 4,349 | $702K |
| 36415 | Collection of venous blood by venipuncture | 10% | 9,618 | 6,579 | $460K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.5% | 14,629 | 12,552 | $418K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.8% | 13,056 | 11,640 | $389K |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.4% | 3,981 | 3,164 | $236K |
| 81001 | 4.5% | 12,819 | 11,245 | $197K | |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.4% | 7,235 | 6,036 | $196K |
| 80053 | Comprehensive metabolic panel | 4.1% | 14,457 | 11,273 | $183K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.9% | 3,537 | 3,173 | $173K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 3.7% | 1,695 | 1,531 | $163K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.9% | 3,043 | 2,593 | $85K |
| 81025 | 1.6% | 10,257 | 9,242 | $72K |
175 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.6% | 6,908 | $69K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.4% | 1,259 | $61K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 1.4% | 1,889 | $60K |
| J3490 | Unclassified drugs | 1.1% | 344 | $50K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 3,840 | $49K |
| S0028 | Injection, famotidine, 20 mg | 1.1% | 1,112 | $48K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,971 | $37K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 783 | $36K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,397 | $35K |
| G0378 | Hospital observation service, per hour | <1% | 6,911 | $34K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,282 | $33K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,447 | $31K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,229 | $31K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,077 | $29K |
| 76801 | <1% | 2,006 | $28K | |
| 71045 | Radiologic examination, chest; single view | <1% | 7,316 | $27K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 498 | $25K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 885 | $22K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,035 | $21K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 18,946 | $19K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 7,269 | $19K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 552 | $17K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 923 | $17K |
| 82962 | <1% | 4,508 | $15K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,707 | $14K |
| 87070 | <1% | 1,546 | $13K | |
| 87449 | <1% | 694 | $13K | |
| 76830 | Ultrasound, transvaginal | <1% | 397 | $13K |
| J1815 | Injection, insulin, per 5 units | <1% | 1,202 | $12K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 566 | $12K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,519 | $12K |
| 73562 | <1% | 762 | $11K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 575 | $10K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,264 | $10K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,598 | $9K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 368 | $9K |
| 73130 | <1% | 362 | $8K | |
| 73630 | <1% | 680 | $7K | |
| 85610 | <1% | 6,890 | $7K | |
| 85730 | <1% | 6,619 | $7K | |
| A9270 | Non-covered item or service | <1% | 2,162 | $7K |
| 73610 | <1% | 451 | $7K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,265 | $6K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 715 | $6K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 766 | $5K |
| 84484 | <1% | 6,460 | $5K | |
| 73030 | <1% | 470 | $5K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,200 | $5K |
| 96376 | <1% | 2,288 | $5K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,228 | $4K |
| 72100 | <1% | 564 | $4K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 280 | $4K |
| 93970 | <1% | 327 | $4K | |
| 97116 | <1% | 434 | $4K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 132 | $4K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,139 | $4K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 269 | $4K |
| 83690 | <1% | 4,684 | $3K | |
| 83880 | <1% | 2,311 | $3K | |
| 82550 | <1% | 3,239 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,041 | $3K |
| 84702 | <1% | 3,712 | $3K | |
| 97162 | <1% | 147 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,118 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,402 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,001 | $2K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,486 | $2K |
| 87430 | <1% | 861 | $2K | |
| 93971 | <1% | 202 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 660 | $2K |
| 72040 | <1% | 165 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,030 | $2K |
| 76641 | <1% | 67 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,069 | $2K |
| 86900 | <1% | 2,220 | $2K | |
| 87040 | <1% | 1,455 | $2K | |
| A4217 | Sterile water/saline, 500 ml | <1% | 363 | $2K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 183 | $2K |
| 12001 | <1% | 47 | $1K | |
| 59025 | Fetal non-stress test | <1% | 156 | $1K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 131 | $1K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,048 | $1K |
| 96367 | <1% | 23 | $1K | |
| 87081 | <1% | 182 | $1K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 58 | $1K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 742 | $974.40 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 725 | $943.74 |
| 86850 | <1% | 1,308 | $910.56 | |
| 74018 | <1% | 163 | $907.38 | |
| 72131 | <1% | 97 | $855.44 | |
| 83735 | <1% | 2,025 | $799.98 | |
| 73110 | <1% | 124 | $778.77 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,090 | $757.31 |
| 97166 | <1% | 56 | $754.49 | |
| 90714 | <1% | 554 | $707.27 | |
| 83605 | <1% | 1,118 | $691.86 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 14 | $630.63 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 544 | $618.39 |
| 80061 | Lipid panel | <1% | 351 | $614.16 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,017 | $602.75 |
| 86901 | <1% | 2,220 | $596.34 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 713 | $591.72 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 674 | $587.81 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 120 | $560.48 |
| 87186 | <1% | 1,673 | $542.88 | |
| 84703 | <1% | 1,405 | $536.50 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 553 | $534.51 |
| 86592 | <1% | 268 | $514.79 | |
| 73140 | <1% | 15 | $495.08 | |
| 85379 | <1% | 1,058 | $469.23 | |
| 87077 | <1% | 1,649 | $444.60 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 571 | $433.63 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,178 | $430.61 |
| 10060 | <1% | 15 | $417.36 | |
| 82805 | <1% | 66 | $391.19 | |
| 73590 | <1% | 43 | $378.49 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 16 | $375.51 |
| 73620 | <1% | 31 | $373.16 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 402 | $368.49 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 698 | $310.74 |
| 80076 | <1% | 523 | $303.50 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 57 | $298.45 |
| 73080 | <1% | 14 | $288.62 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 567 | $272.01 |
| 85045 | <1% | 49 | $270.24 | |
| 72170 | <1% | 117 | $223.45 | |
| 84145 | <1% | 569 | $201.47 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 402 | $196.22 |
| 71250 | <1% | 40 | $188.09 | |
| 87210 | <1% | 574 | $186.67 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 910 | $182.75 |
| 86140 | <1% | 736 | $170.89 | |
| 87205 | <1% | 932 | $150.88 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 837 | $149.51 |
| 84100 | <1% | 1,100 | $125.01 | |
| 73502 | <1% | 70 | $117.65 | |
| 85651 | <1% | 152 | $112.57 | |
| 74022 | <1% | 109 | $101.65 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 475 | $97.98 |
| 87899 | <1% | 555 | $86.40 | |
| 84550 | <1% | 58 | $81.11 | |
| 12011 | <1% | 18 | $80.93 | |
| 82150 | <1% | 243 | $77.54 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 157 | $51.79 |
| 29125 | <1% | 38 | $39.90 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 584 | $33.16 |
| 83615 | <1% | 117 | $32.43 | |
| 80164 | <1% | 14 | $32.40 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 169 | $29.02 |
| 84439 | <1% | 338 | $24.39 | |
| 70486 | <1% | 33 | $17.05 | |
| 87340 | <1% | 42 | $6.87 | |
| 87076 | <1% | 100 | $6.62 | |
| 82010 | <1% | 78 | $6.33 | |
| 86703 | <1% | 43 | $4.37 | |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 34 | $2.20 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 82 | $2.20 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 50 | $2.20 |
| 87185 | <1% | 14 | $1.86 | |
| 73090 | <1% | 12 | $1.10 | |
| 88304 | <1% | 17 | $1.10 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 70 | $1.10 |
| 85384 | <1% | 129 | $1.10 | |
| 36600 | <1% | 46 | $0.58 | |
| 82607 | <1% | 47 | $0.55 | |
| 87147 | <1% | 13 | $0.55 | |
| 82947 | <1% | 48 | $0.55 | |
| 82728 | 0% | 127 | $0.00 | |
| J0456 | Injection, azithromycin, 500 mg | 0% | 31 | $0.00 |
| 82746 | 0% | 15 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 27 | $0.00 |
| J3590 | Unclassified biologics | 0% | 15 | $0.00 |
| 99218 | 0% | 93 | $0.00 | |
| 85007 | 0% | 38 | $0.00 | |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialARMIN, CRAIG (VP OF GOVT PROGRAMS, TENET)
| Provider | Location | Paid |
|---|---|---|
| Lifemark Hospitals of Florida, INC. | Hialeah, FL | $7.11M |
| Hialeah Hospital INC. | Hialeah, FL | $3.62M |
| North Shore Medical Center, INC. | Lauderdale Lakes, FL | $2.52M |
| CGH Hospital, LTD. | Coral Gables, FL | $1.67M |
| VHS West Suburban Medical Center INC | Oak Park, IL | $1.46M |
| VHS Westlake Hospital INC | Melrose Park, IL | $326K |
| Tenet Healthsystem ST. Christopher's Hospital for Children, LLC | Philadelphia, PA | $22K |
| FMC Hospital, LTD. | Lauderdale Lakes, FL | $4K |
| San Dimas Community Hospital, INC. | San Dimas, CA | $963.01 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.